The invention comprises novel chiral metal complex compounds of the formula ##STR00001## wherein M, PR.sup.2, R.sup.3 and R.sup.4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter ion. The chiral metal complex compounds can be used in asymmetric reactions, particularly in asymmetric reductions of ketones, imines or oximes.

The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.

The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.

Disclosed herein are metal complexes that exhibit multiple radiative decay mechanisms, together with methods for the preparation and use thereof.

Disclosed herein are metal complexes that exhibit multiple radiative decay mechanisms, together with methods for the preparation and use thereof.

The present application discloses a method of preparing a luminescent nano-sheet. The method includes preparing a precursor emulsion solution containing a metal halide and RNH.sub.3X, and having a molar ratio of metal halide to RNH.sub.3X in a range of approximately 0.6 to approximately 0.8; demulsifying the precursor emulsion solution to obtain a perovskite quantum dots material and a demulsified solution; and forming the luminescent nano-sheet by allowing the perovskite quantum dots material self-assemble into the luminescent nano-sheet. X is a halide, R is selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heterocyclyl.

The present application discloses a method of preparing a luminescent nano-sheet. The method includes preparing a precursor emulsion solution containing a metal halide and RNH.sub.3X, and having a molar ratio of metal halide to RNH.sub.3X in a range of approximately 0.6 to approximately 0.8; demulsifying the precursor emulsion solution to obtain a perovskite quantum dots material and a demulsified solution; and forming the luminescent nano-sheet by allowing the perovskite quantum dots material self-assemble into the luminescent nano-sheet. X is a halide, R is selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heterocyclyl.

Compositions and methods for adsorption of a species (e.g., ammonia, water, a halogen) comprising metal organic frameworks (MOFs) are generally provided. In some embodiments, a MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two unsaturated N-heterocyclic aromatic groups arranged about an organic core.

Compositions and methods for adsorption of a species (e.g., ammonia, water, a halogen) comprising metal organic frameworks (MOFs) are generally provided. In some embodiments, a MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two unsaturated N-heterocyclic aromatic groups arranged about an organic core.

Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X.sub.3(HCA).sub.2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.